Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
An Open-label, Randomized, Multi-center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients: An Extension Study
Sponsor: Mylan GmbH
This PHASE3 trial investigates Type 1 Diabetes Mellitus and is currently completed. Mylan GmbH leads this study, which shows 11 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Oct 2018 — Oct 2020 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mylan GmbH
- Mylan Inc.
For direct contact, visit the study record on ClinicalTrials.gov .